<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144677</url>
  </required_header>
  <id_info>
    <org_study_id>03-290</org_study_id>
    <nct_id>NCT00144677</nct_id>
  </id_info>
  <brief_title>Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation</brief_title>
  <official_title>Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After HLA-Matched, Unrelated, Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus&#xD;
      host disease (GVHD) in patients following stem cell transplant from an unrelated donor. This&#xD;
      trial is designed to test the hypothesis that elimination of methotrexate in the unrelated&#xD;
      donor group would lead to less transplant-related toxicity while still preserving the&#xD;
      effective control of GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Therapy to prevent GVHD will consist of an infusion of tacrolimus intravenously and&#xD;
           sirolimus orally once daily starting 3 days before stem cell infusion. This will take&#xD;
           place in the hospital where the patient will remain for the duration of the transplant.&#xD;
&#xD;
        -  Sirolimus will continue for approximately 100 days at a stable dose, then it will be&#xD;
           tapered slowly over the course of weeks to months to prevent a flare in GVHD.&#xD;
&#xD;
        -  Patients will be seen in the clinic weekly for the first 2 months after discharge from&#xD;
           the hospital. If GVHD is present, tapering schedule will be slower and based on the&#xD;
           patient's clinical condition.&#xD;
&#xD;
        -  Tacrolimus will also be given orally after the patient is discharged and will be tapered&#xD;
           on the same schedule as sirolimus.&#xD;
&#xD;
        -  During the year following stem cell transplant, blood tests will be performed to&#xD;
           evaluate the immune system and graft versus host disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of using a combination of sirolimus and tacrolimus without methotrexate for GVHD prophylaxis after stem cell transplantation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the rates of grade II-IV and III-IV acute GVHD with historical control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the incidence of 100 day mortality using this GVHD prophylaxis regimen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the overall survival after one year of this patient population.</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myelogenous leukemia(AML) in first or subsequent remission, in untreated first&#xD;
             relapse or any treated relapse.&#xD;
&#xD;
          -  Acute lymphoblastic leukemia(ALL) in first or subsequent remission, in untreated first&#xD;
             relapse or any treated relapse.&#xD;
&#xD;
          -  Chronic myelogenous leukemia in first or second chronic stable phase or in accelerated&#xD;
             phase.&#xD;
&#xD;
          -  Myelodysplastic syndromes or myeloproliferative diseases&#xD;
&#xD;
          -  Non-Hodgkin's lymphoma or Hodgkin's disease in second or greater complete remission,&#xD;
             in partial remission, or induction failure.&#xD;
&#xD;
          -  Chronic lymphocytic leukemia, Rai stage 2-4, which has progressed after initial&#xD;
             therapy.&#xD;
&#xD;
          -  Matched unrelated donor.&#xD;
&#xD;
          -  Age 18-55 years at the time of stem cell transplantation&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy of 100 days without stem cell transplantation&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  AST &lt; 90 IU&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Ejection fraction &gt; 40% by echocardiogram or gated nuclear medicine study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Forced vital capacity or DLCO &lt; 50% predicted for age&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Prior hematopoietic stem cell transplant&#xD;
&#xD;
          -  Evidence of HIV infection or active Hepatitis B or C infection&#xD;
&#xD;
          -  Cholesterol &gt; 300 mg/dl&#xD;
&#xD;
          -  Relapsed aggressive Burkitt's or Burkitt's-like lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Cutler, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Corey S. Cutler, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Graft versus Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>sirolimus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>Stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

